EBioMedicine (Jun 2019)

Combination of apoptotic T cell induction and self-peptide administration for therapy of experimental autoimmune encephalomyelitisResearch in the context

  • Shimpei Kasagi,
  • Dandan Wang,
  • Pin Zhang,
  • Peter Zanvit,
  • Hua Chen,
  • Dunfang Zhang,
  • Jia Li,
  • Li Che,
  • Takashi Maruyama,
  • Hiroko Nakatsukasa,
  • Ruiqing Wu,
  • Wenwen Jin,
  • Lingyun Sun,
  • WanJun Chen

Journal volume & issue
Vol. 44
pp. 50 – 59

Abstract

Read online

Background: Clinical trials on multiple sclerosis with repeated injections of monoclonal antibodies depleting CD4+ T cells have not resulted in much success as a disease therapy. Here, we developed an immunotherapy for EAE in mice by combining a transient depletion of T cells together with the administration of neuron derived peptides. Methods: EAE was induced in SJL and C57BL/6 mice, by proteolipid protein peptide PLP139–151 (pPLP) and myelin-oligodendrocyte glycoprotein MOG35–55 (pMOG) peptides, respectively. Anti-CD4 and anti-CD8 antibody were injected intraperitoneally before or after peptide immunization. EAE scores were evaluated and histology data from brain and spinal cord were analyzed. Splenocytes were isolated and CD4+, CD4+CD25− and CD4+CD25+ T cells were purified and cultured in the presence of either specific peptides or anti-CD3 antibody and proliferation of T cells as well as cytokines in supernatant were assessed. Findings: This experimental treatment exhibited therapeutic effects on mice with established EAE in pPLP-susceptible SJL mice and pMOG-susceptible C57BL/6 mice. Mechanistically, we revealed that antibody-induced apoptotic T cells triggered macrophages to produce TGFβ, and together with administered auto-antigenic peptides, generated antigen-specific Foxp3+ regulatory T cells (Treg cells) in vivo. Interpretation: We successfully developed a specific immunotherapy to EAE by generating autoantigen-specific Treg cells. These findings have overcome the drawbacks of long and repeated depletion of CD4+ T cells, but also obtained long-term immune tolerance, which should have clinical implications for the development of a new effective therapy for multiple sclerosis. Fund: This research was supported by the Intramural Research Program of the NIH, NIDCR.